Citius Oncology, Inc. CTOR Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s cash provided by (used in) investing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s cash provided by (used in) investing activity, including discontinued operation?
- Citius Oncology, Inc. (CTOR) reported cash provided by (used in) investing activity, including discontinued operation of -$600K in Q1 2026.
- How has Citius Oncology, Inc.'s cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
- Citius Oncology, Inc.'s cash provided by (used in) investing activity, including discontinued operation increased by 58.3% year-over-year, from -$1.44M to -$600K.
- What is the long-term trend for Citius Oncology, Inc.'s cash provided by (used in) investing activity, including discontinued operation?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s cash provided by (used in) investing activity, including discontinued operation has grown at a -70.8% compound annual growth rate (CAGR), from -$67.32M to -$5.75M.
- What does cash provided by (used in) investing activity, including discontinued operation mean?
- The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.